ETF Holdings Breakdown of IMNM

Stock NameImmunome Inc
TickerIMNM(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45257U1088

News associated with IMNM

MetLife Investment Management LLC Purchases 5,354 Shares of Immunome, Inc. (NASDAQ:IMNM)
MetLife Investment Management LLC increased its holdings in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 17.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 35,619 shares of the company’s stock after acquiring an additional 5,354 shares during the quarter. MetLife Investment Management LLC’s holdings in Immunome were worth $378,000 at the […] - 2025-05-07 09:00:48
Barclays PLC Sells 1,572 Shares of Immunome, Inc. (NASDAQ:IMNM)
Barclays PLC decreased its position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 1.5% in the 4th quarter, HoldingsChannel reports. The firm owned 104,314 shares of the company’s stock after selling 1,572 shares during the quarter. Barclays PLC’s holdings in Immunome were worth $1,107,000 at the end of the most recent reporting period. […] - 2025-05-05 08:26:54
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $25.33
Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has received an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in […] - 2025-05-05 06:14:50
Renaissance Technologies LLC Purchases 304,700 Shares of Immunome, Inc. (NASDAQ:IMNM)
Renaissance Technologies LLC increased its position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 2,696.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 316,000 shares of the company’s stock after acquiring an additional 304,700 shares during the […] - 2025-04-24 07:50:55
JPMorgan Chase & Co. Has $6.89 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)
JPMorgan Chase & Co. raised its holdings in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 2,540.4% in the 4th quarter, HoldingsChannel reports. The fund owned 648,610 shares of the company’s stock after acquiring an additional 624,045 shares during the period. JPMorgan Chase & Co.’s holdings in Immunome were worth $6,888,000 at the end of the […] - 2025-04-17 07:27:20
Corient Private Wealth LLC Sells 12,149 Shares of Immunome, Inc. (NASDAQ:IMNM)
Corient Private Wealth LLC trimmed its position in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 50.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 12,085 shares of the company’s stock after selling 12,149 shares during the period. Corient Private Wealth LLC’s holdings in Immunome were worth […] - 2025-04-02 07:22:52
Immunome, Inc. (NASDAQ:IMNM) Holdings Increased by Intech Investment Management LLC
Intech Investment Management LLC increased its stake in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 26.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,961 shares of the company’s stock after acquiring an additional 3,974 shares during the period. Intech […] - 2025-03-27 08:03:10
Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Sequoia Financial Advisors LLC
Sequoia Financial Advisors LLC grew its position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 11.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 19,065 shares of the company’s stock after purchasing an additional 2,000 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Immunome were worth $202,000 as of its […] - 2025-03-21 08:24:53
AlphaQuest LLC Raises Stock Position in Immunome, Inc. (NASDAQ:IMNM)
AlphaQuest LLC grew its stake in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 786,700.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,868 shares of the company’s stock after acquiring an additional 7,867 shares during the […] - 2025-03-19 08:20:57
Immunome (NASDAQ:IMNM) Now Covered by Lifesci Capital
Investment analysts at Lifesci Capital assumed coverage on shares of Immunome (NASDAQ:IMNM – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $20.00 price target on the stock. Lifesci Capital’s price objective suggests a potential upside of 117.16% from the company’s current […] - 2025-03-13 07:08:48
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity
Immunome, Inc. (NASDAQ:IMNM – Get Free Report)’s stock price gapped up prior to trading on Tuesday following insider buying activity. The stock had previously closed at $10.32, but opened at $11.16. Immunome shares last traded at $10.87, with a volume of 472,104 shares trading hands. Specifically, CEO Clay B. Siegall purchased 150,000 shares of the […] - 2025-02-06 06:10:43

IMNM institutional holdings

The following institutional investment holdings of IMNM have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 37,908USD 292,271
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 69,832USD 538,405 3.6%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,929USD 14,873
Total =109,669 USD 845,549
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.